Publication:
Non-Invasive Transcutaneous Vagus Nerve Stimulation for the Treatment of Fibromyalgia Symptoms: A Study Protocol.

dc.contributor.authorMolero-Chamizo, Andrés
dc.contributor.authorNitsche, Michael A
dc.contributor.authorBolz, Armin
dc.contributor.authorAndújar Barroso, Rafael Tomás
dc.contributor.authorAlameda Bailén, José R
dc.contributor.authorGarcía Palomeque, Jesús Carlos
dc.contributor.authorRivera-Urbina, Guadalupe Nathzidy
dc.date.accessioned2023-05-03T13:49:00Z
dc.date.available2023-05-03T13:49:00Z
dc.date.issued2022-01-12
dc.description.abstractStimulation of the vagus nerve, a parasympathetic nerve that controls the neuro-digestive, vascular, and immune systems, induces pain relief, particularly in clinical conditions such as headache and rheumatoid arthritis. Transmission through vagal afferents towards the nucleus of the solitary tract (NST), the central relay nucleus of the vagus nerve, has been proposed as the main physiological mechanism that reduces pain intensity after vagal stimulation. Chronic pain symptoms of fibromyalgia patients might benefit from stimulation of the vagus nerve via normalization of altered autonomic and immune systems causing their respective symptoms. However, multi-session non-invasive vagal stimulation effects on fibromyalgia have not been evaluated in randomized clinical trials. We propose a parallel group, sham-controlled, randomized study to modulate the sympathetic-vagal balance and pain intensity in fibromyalgia patients by application of non-invasive transcutaneous vagus nerve stimulation (tVNS) over the vagal auricular and cervical branches. We will recruit 136 fibromyalgia patients with chronic moderate to high pain intensity. The primary outcome measure will be pain intensity, and secondary measures will be fatigue, health-related quality of life, sleep disorders, and depression. Heart rate variability and pro-inflammatory cytokine levels will be obtained as secondary physiological measures. We hypothesize that multiple tVNS sessions (five per week, for 4 weeks) will reduce pain intensity and improve quality of life as a result of normalization of the vagal control of nociception and immune-autonomic functions. Since both vagal branches project to the NST, we do not predict significantly different results between the two stimulation protocols.
dc.identifier.doi10.3390/brainsci12010095
dc.identifier.issn2076-3425
dc.identifier.pmcPMC8774206
dc.identifier.pmid35053839
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774206/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/2076-3425/12/1/95/pdf?version=1641972152
dc.identifier.urihttp://hdl.handle.net/10668/20850
dc.issue.number1
dc.journal.titleBrain sciences
dc.journal.titleabbreviationBrain Sci
dc.language.isoen
dc.organizationServicio Andaluz de Salud-SAS
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectchronic pain
dc.subjectfibromyalgia
dc.subjecttranscutaneous
dc.subjectvagus nerve stimulation
dc.titleNon-Invasive Transcutaneous Vagus Nerve Stimulation for the Treatment of Fibromyalgia Symptoms: A Study Protocol.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number12
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC8774206.pdf
Size:
1.19 MB
Format:
Adobe Portable Document Format